Rebel Medicine Secures Series A Financing to Propel Clinical Development
Rebel Medicine Inc has reached a significant milestone after securing $6 million in Series A financing aimed at promoting the development of its groundbreaking non-opioid pain therapeutic. The company, known for its innovative approaches to drug delivery and pain management, has now set its sights on advancing its lead candidate, Alevatrix™, into clinical trials.
Key Details of the Series A Financing
This Series A round was spearheaded by Crocker Ventures, alongside investments from Central Texas Angel Network (CTAN), Prosperity Solutions Capital, Utah Innovation Fund, and several other prominent life-science angel investors. This influx of capital comes at an opportune time as the company is also opening its Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA.
What to Expect from the IND Application
The formal launch of the IND application signals an exciting phase for Rebel Medicine. It opens the door for Alevatrix™ to enter a first-in-human clinical trial designed to evaluate its safety and effectiveness in post-operative bunionectomy patients. This randomized, dose-escalation, active-controlled Phase 2 clinical trial will be a critical step in assessing the therapeutic’s potential to provide significant pain relief without the reliance on opioids.
Leadership's Vision
Dr. Brett Davis, Co-Founder and CEO of Rebel Medicine, expressed that this funding round validates their vision and the innovative potential of their non-opioid therapies. The combination of the successful fundraising and the IND approval empowers Rebel Medicine to speed up the development cycle for Alevatrix™, highlighting the urgency of addressing the opioid epidemic.
Innovative Approach of Alevatrix™
At the heart of Rebel Medicine's strategy is Alevatrix™, a novel formulation of bupivacaine. This local anesthetic is encapsulated in the company’s proprietary matrix, allowing for prolonged drug release at the site of administration for up to 72 hours. The goal behind Alevatrix™ is to minimize or eliminate opioid use in post-surgical settings, thereby reducing the risks associated with traditional opioid medications.
About Rebel Medicine Inc
Rebel Medicine is a privately held biotechnology firm that prides itself on enhancing the capabilities of established pharmaceuticals through advanced drug delivery technologies. With headquarters in Salt Lake City, the company is focused on developing high-value therapeutic solutions that meet unmet medical needs while striving to decrease the time, cost, and risks associated with bringing new drugs to market.
Ongoing Efforts and Future Prospects
Rebel Medicine's lead product, Alevatrix™, is just the starting point in an expanding portfolio of innovations designed for non-opioid post-operative pain management. The company is actively developing additional programs utilizing their proprietary systems to extend the release of injectable medications from days to potentially months, catering to a diverse array of therapeutic needs.
Connecting with the Community
Rebel Medicine encourages interested individuals to stay informed about the company’s progress by connecting through professional platforms. They aim to build a community around their mission, focusing on innovations that prioritize patient safety and effective pain management solutions.
Frequently Asked Questions
1. What is Rebel Medicine's main focus?
Rebel Medicine specializes in developing non-opioid pain therapeutics and advanced drug delivery systems aimed at managing acute and post-operative pain.
2. What recent funding milestone has Rebel Medicine achieved?
Rebel Medicine recently secured $6 million in Series A financing to accelerate the development of its lead candidate, Alevatrix™.
3. What does the IND application open for Alevatrix™?
The IND application allows for the commencement of clinical trials to assess the safety and efficacy of Alevatrix™ in patients undergoing surgery.
4. How does Alevatrix™ work?
Alevatrix™ is a long-acting formulation of bupivacaine that releases medication at the site of administration for up to 72 hours to minimize opioid use post-surgery.
5. How can I learn more about Rebel Medicine's innovations?
To stay updated with Rebel Medicine's advancements, connect with the company through their LinkedIn page or visit their official website for news and updates.
